The hormonal treatment in prostate cancer

被引：6
作者：
Bastide, C. [1 ]
Bruyere, F. [2 ]
Karsenty, G. [3 ]
Guy, L. [4 ]
Rozet, F. [5 ]
机构：
[1] Aix Marseille Univ, Hop Nord, AP HM, Serv Urol, F-13015 Marseille, France
[2] Univ Tours, CHRU Bretonneau, PRES Ctr Val De Loire Univ, Serv Urol, F-37000 Tours, France
[3] Aix Marseille Univ, Hop Concept, AP HM, Serv Urol & Transplantat Renale, F-13385 Marseille 5, France
[4] Univ Auvergne, Hop G Montpied, Serv Urol, F-63003 Clermont Ferrand 1, France
[5] Inst Mutualiste Montsouris, Serv Urol, F-75014 Paris, France
来源：
PROGRES EN UROLOGIE | 2013年 / 23卷 / 15期
关键词：
Prostate cancer; Hormonal treatment; LHRH analogs; Degarelix; Antiandrogens; Diethylstilbestrol; Estramustin; Abiraterone acetate; Enzalutamid; ANDROGEN DEPRIVATION THERAPY; GROUP PHASE-III; BICALUTAMIDE MONOTHERAPY; CYPROTERONE-ACETATE; INCREASED SURVIVAL; RADIATION-THERAPY; MG MONOTHERAPY; CASTRATION; FLUTAMIDE; TRIAL;
D O I：
10.1016/j.purol.2013.08.325
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Aim. - To describe drugs used in the hormonal treatment (hormonotherapy) of prostate cancer. Material. - Bibliographical search was performed from the database Medline (National Library of Medicine, PubMed) and websites of the HAS and the ANSM. The search was focused on the characteristics, the mode of action, the efficiency and the side effects of the various drugs concerned. Results. - LHRH analogs and the antiandrogens remain the cornerstone in the treatment of locally advanced and metastatic prostate cancer. New therapeutic classes emerged recently (inhibitor of the synthesis of the androgen, the new antiandrogens) and allowed to grow again the limits of the hormone resistance and define the concept castration-resistant prostate cancer. Conclusion -. The hormonal treatment of the prostate cancer grew rich of new therapeutic classes which are going to change the medical care of the prostate cancer in the coming years and the urologist must play its full part. (C) 2013 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：1246 / 1257
页数：12
相关论文
共 55 条
[1]   A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer [J].
Bales, GT ;
Chodak, GW .
UROLOGY, 1996, 47 (1A) :38-43
[2]   Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: Results of an Italian Prostate Cancer Project study [J].
Boccardo, F ;
Rubagotti, A ;
Borichello, M ;
Battaglia, M ;
Carmignani, G ;
Comeri, G ;
Conti, G ;
Cruciani, G ;
Dammino, S ;
Delliponti, U ;
Ditonno, P ;
Ferraris, V ;
Lilliu, S ;
Montefiore, F ;
Portoghese, F ;
Spano, G .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2027-2038
[3]   Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma [J].
Studer, UE .
EUROPEAN UROLOGY, 1997, 32 (04) :395-396
[4]   Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial [J].
Bolla, M ;
Collette, L ;
Blank, L ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Mattelaer, J ;
Torecilla, JL ;
Pfeffer, JR ;
Cutajar, CL ;
Zurlo, A ;
Pierart, M .
LANCET, 2002, 360 (9327) :103-108
[5]   Duration of Androgen Suppression in the Treatment of Prostate Cancer [J].
Bolla, Michel ;
de Reijke, Theodorus M. ;
Van Tienhoven, Geertjan ;
Van den Bergh, Alphonsus C. M. ;
Oddens, Jorg ;
Poortmans, Philip M. P. ;
Gez, Eliahu ;
Kil, Paul ;
Akdas, Atif ;
Soete, Guy ;
Kariakine, Oleg ;
Van der Steen-Banasik, Elsbietha M. ;
Musat, Elena ;
Pierart, Marianne ;
Mauer, Murielle E. ;
Collette, Laurence .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (24) :2516-2527
[6]   Is the flare phenomenon clinically significant? [J].
Bubley, GJ .
UROLOGY, 2001, 58 (2A) :5-9
[7]   Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: Flutamide versus diethylstilbestrol [J].
Chang, A ;
Yeap, B ;
Davis, T ;
Blum, R ;
Hahn, R ;
Khanna, O ;
Fisher, H ;
Rosenthal, J ;
Witte, R ;
Schinella, R ;
Trump, D .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (08) :2250-2257
[8]   Update on the use of estramustin in metastatic prostate cancer [J].
Culine, S. ;
Drouet, L. ;
Eymard, J. -C. ;
Fizazi, K. ;
Gravis, G. ;
Hennequin, C. ;
Oudard, S. ;
Ravery, V. ;
Zerbib, M. .
PROGRES EN UROLOGIE, 2010, 20 (01) :24-29
[9]   Androgen suppression and radiation vs radiation alone for prostate cancer - A randomized trial [J].
D'Amico, Anthony V. ;
Chen, Ming-Hui ;
Renshaw, Andrew A. ;
Loffredo, Marian ;
Kantoff, Philip W. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (03) :289-295
[10]   6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer - A randomized controlled trial [J].
D'Amico, AV ;
Manola, J ;
Loffredo, M ;
Renshaw, AA ;
DellaCroce, A ;
Kantoff, PW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (07) :821-827
123456